Therapy of CF-patients with amitriptyline and placebo-a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study

Cellular Physiology and Biochemistry

Volumn 31, Issue 4-5, 2013, Pages 505-512

  Nährlich, Lutz ^a   Mainz, Jochen G ^b   Adams, Constantin ^c   Engel, Corinna ^c   Herrmann, Gloria ^c   Icheva, Vanya ^c   Lauer, Josefine ^c   Deppisch, Caroline ^c   Wirth, Andreas ^c   Unger, Katy ^c   Graepler Mainka, Ute ^c   Hector, Andreas ^c   Heyder, Susanne ^c   Stern, Martin ^c   Döring, Gerd ^c   Gulbins, Erich ^d   Riethmüller, Joachim ^c  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Amitriptyline; Ceramide; CFTR; Cystic Fibrosis; P. aeruginosa

Indexed keywords

AMITRIPTYLINE; CERAMIDE; PLACEBO; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8;

ADULT; ARTICLE; CLINICAL ARTICLE; COMMON COLD; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; HEADACHE; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; MALE; MUCOCILIARY CLEARANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; XEROSTOMIA; CONSTIPATION; CYSTIC FIBROSIS; DRUG EFFICACY; DYSKINESIA; DYSURIA; GLAUCOMA; IN VIVO STUDY; INTENTION TO TREAT ANALYSIS; LONG QT SYNDROME; LUNG FUNCTION; MULTICENTER STUDY; MUSCLE HYPOTONIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; VERTIGO;

MUS;

EID: 84875869921     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350071     Document Type: Article

References (18)

1. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, et al.: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. (Pubitemid 19231813)
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073. (Pubitemid 19231814)
3. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080. (Pubitemid 19231815)
4. Ratjen FA: Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009;54:595-605.
5. CF Foundation, Patient Registry Annual Report 2004, Bethesda, Maryland, USA, 2005. http://www.cff.org/UploadedFiles/publications/files/2006
6. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Döring G: Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa CF airways infection. J Clin Invest 2002;109:317-325.
7. Döring G, Hoiby N, for the Consensus Study Group: Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004;3:67-91. (Pubitemid 38987019)
8. Ramsey BW, Davies J, McElvaney NG, Tullies E, Bell SC, D?evínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS, VX08-770-102 Study Group: A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. New Engl J Med 2011;365:1663-1672.
9. Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassmé H, Döring G, Gulbins E: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391. (Pubitemid 351499396)
10. Brodlie M, McKean MC, Johnson GE, Gray J, Fisher AJ, Corris PA, Lordan JL, Ward C: Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 2010;182:369-375.
11. Bodas M, Min T, Mazur S, Vij N: Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 2010;186:602-613.
12. Bodas M, Min T, Vij N: Critical role of CFTR-dependent lipid rafts in cigarette smoke-induced lung epithelial injury. Am J Physiol Lung Cell Mol Physiol 2011;300:L811-820.
13. Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressants desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 1994;375:447-450. (Pubitemid 2120332)
14. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E: Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. J Med Chem 2008;51:219-237.
15. Riethmueller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E: Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 2009;24:65-72.
16. Riethmueller J, Vonthein R, Borth-Bruhns T, Grassmé H, Eyrich M, Schilbach K, Stern M, Gulbins E: DNA quantification and fragmentation in sputum after inhalation of recombinant human deoxyribonuclease. Cell Physiol Biochem 2008;22:347-352.
17. Parker AC, Pritchard P, Preston T, Smyth RL, Choonara I: Enhanced drug metabolism in young children with cystic fibrosis. Arch Dis Childhood 1997;77:239-241. (Pubitemid 27422032)
18. Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E: Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330. (Pubitemid 36362788)